

26. (New) A method for treating cancer, said method comprising administering to a subject in need thereof an effective amount of a first compound that activates the IL-12 receptor, IL-15 receptor or IL-18 receptor and an effective amount of a second compound that activates 4-1BB, wherein the first compound is a cytokine or a nucleic acid molecule comprising a nucleotide sequence encoding a cytokine and the second compound is 4-1BB ligand, a fragment, analog or derivative thereof, or a nucleic acid molecule comprising a nucleotide sequence encoding 4-1BB ligand, a fragment, analog or derivative thereof.

27. (New) A method for treating cancer, said method comprising administering to a subject in need thereof an effective amount of 4-1BB ligand or a fragment, derivative or analog thereof that activates 4-1BB and an effective amount of a nucleic acid molecule comprising a nucleotide sequence encoding a cytokine that activates the IL-15 receptor or IL-18 receptor.

28. (New) A method for treating cancer, said method comprising administering to a subject in need thereof an effective amount of 4-1BB ligand or a fragment, derivative or analog thereof that activates 4-1BB and an effective amount of a nucleic acid molecule comprising the nucleotide sequence encoding IL-12 or a fragment, derivative or analog thereof that activates the IL-12 receptor.

29. (New) The method of Claim 28, wherein the expression of the nucleotide sequence encoding IL-12 or a fragment, derivative or analog thereof is regulated by a constitutive, inducible or tissue-specific promoter.

30. (New) The method of Claim 28, wherein the nucleic acid molecule is contained in an expression vector.

31. (New) The method of Claim 28, wherein the nucleic acid molecule is contained in a viral vector.

32. (New) The method of Claim 31, wherein the viral vector is an adenovirus vector.

33. (New) The method of Claim 31, wherein the viral vector is a retroviral vector or an adeno-associated viral vector.

34. (New) The method of Claim 28, wherein the nucleotide sequence encodes human IL-12.

35. (New) The method of Claim 28 in which the subject is non-human mammal.

36. (New) The method of Claim 28 in which the subject is a human.

37. (New) The method of Claim 28, wherein the cancer is pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, lung cancer or hepatic cancer.

REMARKS

Claims 1-25 were pending in this application. Applicants have canceled Claims 1-12 and 14, 16, 18, and 20, drawn to non-elected inventions, without prejudice to Applicants' right to pursue the subject matter of the canceled claims in related applications. Applicants have also canceled Claims 21-25, without prejudice to Applicants' right to pursue the subject matter of the canceled claims in related applications. Applicants have added new Claims 26-27, directed to methods for treating cancer. Support in the specification for the new claims can be found throughout, for example at page 11, line 12 to page 16, line 15, page 27, line 19 to page 33, line 15, and page 23, lines 26-32 of the present specification. Thus, Applicants assert that the new claims do not constitute new matter. Upon entry of this amendment, Claims 13, 15, 17, 19 and 26-37 will be pending in the instant application.

RESPONSE TO RESTRICTION REQUIREMENT

The Examiner has required an election under 35 U.S.C. § 121 of one of the following groups: